Gossamer Bio Inc

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Tellurian

Exela Technologies

Understand these key penny stocks vs. blue chips differences The post Penny Stocks Vs.

Penny Stocks Vs. Blue Chips, 3 Main Differences

Blue Apron

Grom Social Enterprises

Heron Therapeutics

PLBY Group

Transocean

Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch

Penny Stocks To Buy Now? 3 Short Squeeze Stocks To Watch

Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept.

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Gossamer Bio Inc stock lost three quarters of its value today as the market questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial despite an upbeat assessment from the company. “We are very pleased to share that seralutinib significantly improved hemodynamic, biomarker, and right heart structural and functional measures in a heavily treated pulmonary arterial hypertension patient population,” said Faheem Hasnain, CEO of Gossamer.

Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial

Gossamer Bio (NASDAQ: GOSS ) is one of the top-trending tickers on social media today, and its shares are plunging more than 70%. The company announced that a trial of its drug for hypertension, seralutinib, had met the primary goal in a Phase 2 trial.

Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?

Shares of Gossamer Bio Inc. GOSS, +2.99% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s MRK, -0.03% sotatercept.

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

SAN DIEGO--( BUSINESS WIRE )--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Gossamer Bio (GOSS) a New Buy Stock

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the third quarter ended September 30, 2022 and provided a business update.

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside.

This little-known biopharma stock could rally 70%: Goldman Sachs

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Catalyst Pharmaceuticals

Verona Pharma

Akero Therapeutics Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter ended June 30, 2022 and provided a business update. “Everyone at Gossamer is looking forward to the upcoming TORREY Phase 2 results, as we actively prepare for seralutinib's next steps in cl

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Gossamer Bio (GOSS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High?

Mereo Biopharma Group Plc - ADR

Nektar Therapeutics

Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find Penny Stocks to Buy in Summer 2022

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to sell approximately 16.6 million shares of its common stock to a select group of institutional and accredited investors in a private placement, at a price per share of $7.21. Gross proceeds are expected to be approximat

Gossamer Bio Announces $120 Million Private Placement Financing

SAN DIEGO--(BUSINESS WIRE)---- $GOSS #ERSpublications--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The article, entitled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arte

Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAH

The mean of analysts' price targets for Gossamer Bio (GOSS) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade

After losing some value lately, a hammer chart pattern has been formed for Gossamer Bio (GOSS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter ended March 31, 2022 and provided a business update. “We are looking forward to the fourth quarter release of topline data from the ongoing Phase 2 TORREY Study, which has now completed enrol

Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

Gossamer Bio Inc (NASDAQ: GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12.

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results from its Phase 2 SHIFT-UC Study clinical trial studying GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12. Based on the

Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. “After a considerable amount of planning and effort, the Gossamer team is excited to enter 2022 with two ongoing Phase 2 tria

Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on

Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022

News for Gossamer Bio Inc Stock (GOSS)